Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients.
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- HK inno.NSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HK inno.N Corporation
- Trial code
- NCT07930169
- Record updated
- 10 November 2026
- Original description
This study will be conducted under routine clinical practice in adults diagnosed with advanced chronic renal failure for whom treatment with Kremezin immediate-release tablets or Kremezin fine granules has been determined as part of standard clinical care. Kremezin will be prescribed and administered in accordance with the approved product labeling. Study data will be collected at up to three time points through Week 48: baseline, Week 24, and Week 48. Effectiveness will be assessed using serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and the investigator's overall assessment; treatment satisfaction and safety information will also be collected.Read full original descriptionShow less
A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients.
This study will be conducted under routine clinical practice in adults diagnosed with advanced chronic renal failure for whom treatment with Kremezin immediate-release tablets or Kremezin fine granules has been determined as part of standard clinical care. Kremezin will be prescribed and administered in accordance with the approved product labeling. Study data will be collected at up to three time points through Week 48: baseline, Week 24, and Week 48. Effectiveness will be assessed using serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and the investigator's overall assessment; treatment satisfaction and safety information will also be collected.
Inclusion: Adults aged 19 years or older diagnosed with advanced chronic renal failure; Individuals who voluntarily decide to participate and provide written informed consent.
Exclusion: Individuals with an active or progressive infection; Individuals with a history of dialysis; Individuals with AST or ALT levels at least three times the upper limit of normal; Individuals for whom Kremezin immediate-release tablets or Kremezin fine granules are contraindicated according to the product labeling; Individuals with chronic alcoholism; Pregnant or breastfeeding individuals.